EraCal Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EraCal Therapeutics Ltd. - overview
Established
2018
Location
Zurich, -, Switzerland
Primary Industry
Biotechnology
About
EraCal Therapeutics Ltd. is a Swiss company specializing in innovative solutions for obesity management, focusing on advanced therapeutic products that enhance metabolic health and facilitate effective weight management. Founded in Zurich, Switzerland in 2018 by Josua Jordi, EraCal Therapeutics Ltd. is dedicated to developing therapeutic interventions for weight management.
The company has engaged in two notable deals, with its most recent funding round being a Seed round in October 2019 that raised CHF 1. 000 mn, led by Life Sciences Fund Amsterdam alongside other investors including Novartis Venture Fund and UZH Life Sciences Fund. EraCal Therapeutics specializes in innovative solutions aimed at combating obesity through a suite of scientifically developed products. The company's primary offerings focus on advanced therapeutic interventions that target metabolic health and weight management, leveraging cutting-edge research and technology to address both physiological and psychological factors contributing to obesity.
EraCal Therapeutics serves a diverse client base, including healthcare providers, wellness centers, and directly to consumers seeking effective weight management solutions, with products distributed across key markets in North America and Europe. EraCal Therapeutics generates revenue through a structured business model that includes direct-to-consumer sales and partnerships with healthcare providers and wellness organizations. The company capitalizes on subscription-based services for its flagship products, ensuring ongoing access to therapeutic solutions and support. By establishing relationships with retailers and wholesalers, EraCal Therapeutics guarantees broader availability of its products, with pricing reflecting the innovative science behind them.
EraCal Therapeutics Ltd. plans to leverage its recent Seed funding, raised in October 2019, to enhance product development and expand its market reach. The company is focused on launching new therapeutic products aimed at improving metabolic health, with plans for introduction in 2022. Additionally, EraCal aims to penetrate new markets in Asia and South America by 2023, responding to the increasing global demand for effective obesity management solutions.
Current Investors
Novartis Venture Fund, Life Sciences Fund Amsterdam, UZH Life Sciences Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.eracal.ch
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
EraCal Therapeutics Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.